153 related articles for article (PubMed ID: 34590123)
1. Cost-effectiveness analysis using lifetime attributable risk of proton beam therapy for pediatric medulloblastoma in Japan.
Yoshimura T; Tamori H; Morii Y; Hashimoto T; Shimizu S; Ogasawara K
J Radiat Res; 2021 Sep; ():. PubMed ID: 34590123
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of cochlear dose reduction by proton beam therapy for medulloblastoma in childhood.
Hirano E; Fuji H; Onoe T; Kumar V; Shirato H; Kawabuchi K
J Radiat Res; 2014 Mar; 55(2):320-7. PubMed ID: 24187330
[TBL] [Abstract][Full Text] [Related]
3. Lifetime attributable risk of radiation-induced secondary cancer from proton beam therapy compared with that of intensity-modulated X-ray therapy in randomly sampled pediatric cancer patients.
Tamura M; Sakurai H; Mizumoto M; Kamizawa S; Murayama S; Yamashita H; Takao S; Suzuki R; Shirato H; Ito YM
J Radiat Res; 2017 May; 58(3):363-371. PubMed ID: 27789564
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the cost-effectiveness of proton beam therapy for unresectable pancreatic cancer in Japan.
Hiroshima Y; Kondo M; Sawada T; Hoshi SL; Okubo R; Iizumi T; Numajiri H; Okumura T; Sakurai H
Cancer Med; 2023 Oct; 12(20):20450-20458. PubMed ID: 37795771
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Proton Versus Photon Therapy in Pediatric Medulloblastoma Treatment: A Patient Volume-Based Analysis.
Fernandes RRA; Vianna CMM; Guerra RL; Cancela MC; Almeida LM; Pereira AJDC; Viégas CMP; Ferman SE; Corrêa F
Value Health Reg Issues; 2019 Dec; 20():122-128. PubMed ID: 31319299
[TBL] [Abstract][Full Text] [Related]
6. Impact of lifetime attributable risk of radiation-induced secondary cancer in proton craniospinal irradiation with vertebral-body-sparing for young pediatric patients with medulloblastoma.
Suzuki S; Kato T; Murakami M
J Radiat Res; 2021 Mar; 62(2):186-197. PubMed ID: 33341899
[TBL] [Abstract][Full Text] [Related]
7. Optimizing oropharyngeal cancer management by using proton beam therapy: trends of cost-effectiveness.
Li G; Xia YF; Huang YX; Okat D; Qiu B; Doyen J; Bondiau PY; Benezery K; Gao J; Qian CN
BMC Cancer; 2021 Aug; 21(1):944. PubMed ID: 34419008
[TBL] [Abstract][Full Text] [Related]
8. A Systematic Review of the Economic Burden of Proton Therapy in Head and Neck Cancer.
Bharathi R P; Ms A; Kamath A
Asian Pac J Cancer Prev; 2023 Nov; 24(11):3643-3653. PubMed ID: 38019221
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of proton therapy in treating base of skull chordoma.
Austin AM; Douglass MJJ; Nguyen GT; Dalfsen R; Le H; Gorayski P; Tee H; Penniment M; Penfold SN
Australas Phys Eng Sci Med; 2019 Dec; 42(4):1091-1098. PubMed ID: 31646441
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of proton beam therapy for treatment decision making in paranasal sinus and nasal cavity cancers in China.
Li G; Qiu B; Huang YX; Doyen J; Bondiau PY; Benezery K; Xia YF; Qian CN
BMC Cancer; 2020 Jun; 20(1):599. PubMed ID: 32590957
[TBL] [Abstract][Full Text] [Related]
11. Individualised Estimation of Quality-adjusted Survival Benefit and Cost-effectiveness of Proton Beam Therapy in Intermediate-stage Hodgkin Lymphoma.
Jones DA; Candio P; Shakir R; Ramroth J; Wolstenholme J; Gray AM; Cutter DJ; Ntentas G
Clin Oncol (R Coll Radiol); 2023 May; 35(5):301-310. PubMed ID: 36732121
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.
Kobayashi T; Hoshi M; Yuasa A; Arai S; Ikeda M; Matsuda H; Kim SW; Hibi T
Pharmacoeconomics; 2023 May; 41(5):589-604. PubMed ID: 36884164
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness Analysis of Intensity Modulated Radiation Therapy Versus Proton Therapy for Oropharyngeal Squamous Cell Carcinoma.
Sher DJ; Tishler RB; Pham NL; Punglia RS
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):875-882. PubMed ID: 29976499
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of proton therapy compared with photon therapy in the management of pediatric medulloblastoma.
Mailhot Vega RB; Kim J; Bussière M; Hattangadi J; Hollander A; Michalski J; Tarbell NJ; Yock T; MacDonald SM
Cancer; 2013 Dec; 119(24):4299-307. PubMed ID: 24105630
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of olanzapine in four-drug antiemetic therapy in Japanese patients treated with highly emetogenic cisplatin-containing chemotherapy.
Kondo Y; Tachi T; Sakakibara T; Kato J; Mizuno T; Miyake Y; Teramachi H
J Pharm Health Care Sci; 2022 Jun; 8(1):15. PubMed ID: 35642015
[TBL] [Abstract][Full Text] [Related]
16. Difference in Cost-Effectiveness between First-Line and Third-Line or Later Nivolumab Therapy in Patients with HER2-Negative, Unresectable, Advanced or Recurrent Gastric or Gastro-Esophageal Junction Cancer in Japan.
Kashiwa M; Matsushita R
Biol Pharm Bull; 2022; 45(7):895-903. PubMed ID: 35786597
[TBL] [Abstract][Full Text] [Related]
17. A systematic review of the cost and cost-effectiveness studies of proton radiotherapy.
Verma V; Mishra MV; Mehta MP
Cancer; 2016 May; 122(10):1483-501. PubMed ID: 26828647
[TBL] [Abstract][Full Text] [Related]
18. Systematic review of the cost effectiveness of radiation therapy for prostate cancer from 2003 to 2013.
Amin NP; Sher DJ; Konski AA
Appl Health Econ Health Policy; 2014 Aug; 12(4):391-408. PubMed ID: 25022451
[TBL] [Abstract][Full Text] [Related]
19. A comparative study on the risks of radiogenic second cancers and cardiac mortality in a set of pediatric medulloblastoma patients treated with photon or proton craniospinal irradiation.
Zhang R; Howell RM; Taddei PJ; Giebeler A; Mahajan A; Newhauser WD
Radiother Oncol; 2014 Oct; 113(1):84-8. PubMed ID: 25128084
[TBL] [Abstract][Full Text] [Related]
20. Does electron and proton therapy reduce the risk of radiation induced cancer after spinal irradiation for childhood medulloblastoma? A comparative treatment planning study.
Mu X; Björk-Eriksson T; Nill S; Oelfke U; Johansson KA; Gagliardi G; Johansson L; Karlsson M; Zackrisson DB
Acta Oncol; 2005; 44(6):554-62. PubMed ID: 16165914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
